PortfoliosLab logoPortfoliosLab logo
BTEC.L vs. BIOT.L
Performance
Return for Risk
Drawdowns
Volatility
Dividends

Performance

BTEC.L vs. BIOT.L - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEC.L) and L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BTEC.L achieves a 15.22% return, which is significantly higher than BIOT.L's 8.27% return.


BTEC.L

1D
0.68%
1M
9.55%
6M
13.18%
YTD
15.22%
1Y
50.31%
3Y*
16.99%
5Y*
5.87%
10Y*

BIOT.L

1D
0.31%
1M
7.79%
6M
7.56%
YTD
8.27%
1Y
33.81%
3Y*
10.20%
5Y*
2.83%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

BTEC.L vs. BIOT.L - Yearly Performance Comparison


2026 (YTD)20252024202320222021202020192018
BTEC.L
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
15.22%32.96%-2.04%6.22%-11.92%-0.49%27.40%25.57%-13.84%
BIOT.L
L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF
8.27%36.47%-5.31%-9.28%-8.41%-3.60%28.29%13.02%-8.12%

Correlation

The correlation between BTEC.L and BIOT.L is 0.88, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.88

Correlation (3Y)
Calculated over the trailing 3-year period

0.83

Correlation (5Y)
Calculated over the trailing 5-year period

0.83

Correlation (All Time)
Calculated using the full available price history since Jan 18, 2018

0.82

The correlation between BTEC.L and BIOT.L has been stable across timeframes, ranging from 0.82 to 0.88 - a consistent structural relationship.

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BTEC.L vs. BIOT.L — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BTEC.L
BTEC.L Risk / Return Rank: 9090
Overall Rank
BTEC.L Sharpe Ratio Rank: 9090
Sharpe Ratio Rank
BTEC.L Sortino Ratio Rank: 8989
Sortino Ratio Rank
BTEC.L Omega Ratio Rank: 8282
Omega Ratio Rank
BTEC.L Calmar Ratio Rank: 9595
Calmar Ratio Rank
BTEC.L Martin Ratio Rank: 9393
Martin Ratio Rank

BIOT.L
BIOT.L Risk / Return Rank: 6767
Overall Rank
BIOT.L Sharpe Ratio Rank: 6363
Sharpe Ratio Rank
BIOT.L Sortino Ratio Rank: 6464
Sortino Ratio Rank
BIOT.L Omega Ratio Rank: 5555
Omega Ratio Rank
BIOT.L Calmar Ratio Rank: 8383
Calmar Ratio Rank
BIOT.L Martin Ratio Rank: 7070
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BTEC.L vs. BIOT.L - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEC.L) and L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


BTEC.LBIOT.LDifference
Sharpe ratioReturn per unit of total volatility

+0.75

Sortino ratioReturn per unit of downside risk

+0.96

Omega ratioGain probability vs. loss probability

1.39

1.28

+0.11

Calmar ratioReturn relative to maximum drawdown

6.22

3.52

+2.70

Martin ratioReturn relative to average drawdown

19.15

10.12

+9.02

BTEC.L vs. BIOT.L - Sharpe Ratio Comparison

The current BTEC.L Sharpe Ratio is 2.42, which is higher than the BIOT.L Sharpe Ratio of 1.67. The chart below compares the historical Sharpe Ratios of BTEC.L and BIOT.L, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

BTEC.L vs. BIOT.L - Drawdown Comparison

The maximum BTEC.L drawdown since its inception was -38.42%, which is greater than BIOT.L's maximum drawdown of -34.44%. Use the drawdown chart below to compare losses from any high point for BTEC.L and BIOT.L.


Loading charts...

Drawdown Indicators


BTEC.LBIOT.LDifference

Max Drawdown

Largest peak-to-trough decline

-38.42%

-34.44%

-3.98%

Max Drawdown (1Y)

Largest decline over 1 year

-7.94%

-9.55%

+1.61%

Max Drawdown (3Y)

Largest decline over 3 years

-26.74%

-19.91%

-6.83%

Max Drawdown (5Y)

Largest decline over 5 years

-38.42%

-33.80%

-4.62%

Current Drawdown

Current decline from peak

-3.87%

-5.72%

+1.85%

Average Drawdown

Average peak-to-trough decline

-13.22%

-13.31%

+0.09%

Ulcer Index

Depth and duration of drawdowns from previous peaks

2.58%

3.33%

-0.75%

Volatility

BTEC.L vs. BIOT.L - Volatility Comparison

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEC.L) and L&G Pharma Breakthrough UCITS ETF - USD Accumulating ETF (BIOT.L) have volatilities of 5.91% and 6.08%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BTEC.LBIOT.LDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.91%

6.08%

-0.17%

Volatility (6M)

Calculated over the trailing 6-month period

15.67%

15.54%

+0.13%

Volatility (1Y)

Calculated over the trailing 1-year period

20.42%

20.18%

+0.24%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

21.39%

18.62%

+2.77%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

22.37%

19.50%

+2.87%

BTEC.L vs. BIOT.L - Expense Ratio Comparison

BTEC.L has a 0.35% expense ratio, which is lower than BIOT.L's 0.49% expense ratio.


Dividends

BTEC.L vs. BIOT.L - Dividend Comparison

Neither BTEC.L nor BIOT.L has paid dividends to shareholders.


Tickers have no history of dividend payments

Frequently Asked Questions


BTEC.L and BIOT.L have a correlation of 0.88, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

On fees, BTEC.L is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.

BTEC.L is cheaper with a 0.35% expense ratio, compared with 0.49% for BIOT.L.

BTEC.L tracks NASDAQ Biotechnology NET Index, while BIOT.L tracks Solactive Pharma Breakthrough Value Index Net Total Return. They also come from different issuers: iShares and L&G. Their fees differ too: 0.35% for BTEC.L and 0.49% for BIOT.L.

Portfolio Optimizer

Find the right allocation for BTEC.L and BIOT.L

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer